-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IhVIhaNYtfd/aMlbFskkbT+gmcJA3O3gPAUBVi3Lm6NsdLHtgRz0vnGc7JtujfaN
 mTCRXqi56tMxppkgi4WpfQ==

<SEC-DOCUMENT>0001104659-04-041367.txt : 20041228
<SEC-HEADER>0001104659-04-041367.hdr.sgml : 20041228
<ACCEPTANCE-DATETIME>20041228144745
ACCESSION NUMBER:		0001104659-04-041367
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041217
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041228
DATE AS OF CHANGE:		20041228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NUVASIVE INC
		CENTRAL INDEX KEY:			0001142596
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330768598
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50744
		FILM NUMBER:		041228341

	BUSINESS ADDRESS:	
		STREET 1:		10065 OLD GROVE RD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
		BUSINESS PHONE:		8582717070
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a04-15357_18k.htm
<DESCRIPTION>8-K
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE
COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Form 8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report<b><font style="font-weight:bold;"> </font></b>(Date of earliest event reported):<b><font style="font-weight:bold;">&#160; December 17, 2004</font></b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">NUVASIVE, INC.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant
as specified in its charter)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">000-50744</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.18%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3</font></b><b><font style="font-weight:bold;">3-0768598</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other
  Jurisdiction of<br>
  Incorporation)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File<br>
  Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.18%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer
  Idenitifcaiton<br>
  Number)</font></p>
  </td>
 </tr>
</table>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10065 Old Grove Road, San Diego,
California&#160; 92131</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal
executive offices, with zip code)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(858) 271-7070</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone
number, including area code)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">n/a</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former name or former
address, if changed since last report)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (<i><font style="font-style:italic;">see</font></i> General Instruction A.2. below):</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</p>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;margin:0in 0in .0001pt 1.0in;padding:0in;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tvalley\04-15357-1\task263848\15357-1-ba.htm',USER='tvalley',CD='Dec 28 12:19 2004' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
5.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.</b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On December 22, 2004, NuVasive, Inc. issued a press
release announcing the promotion of Keith Valentine to the office of President,
effective December 17, 2004.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr. Valentine, age 37, has served as NuVasive&#146;s
Executive Vice President since January 2002. Prior to that, he served as
NuVasive&#146;s Senior Vice President of Marketing &amp; Development from January
2001 to January 2002. From January 2000 to December 2000, Mr. Valentine served
as Vice President of Marketing at ORATEC Interventions, Inc., a medical device
company which was acquired by Smith &amp; Nephew plc, also a medical device
company, in 2002. From January 1992 to January 2000, Mr. Valentine served in
various capacities at Medtronic Sofamor Danek, including Vice President of
Marketing for the Rods Division and Group Director for the BMP Biologics
program, the Interbody Sales Development effort and International Sales and
Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical
Sciences from Western Michigan University.&#160;
Mr. Valentine&#146;s annual salary exceeds $60,000.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A copy of the press release announcing this promotion
is attached as Exhibit 99.1 hereto.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The disclosure contained in this Item 5.02 is provided
on a delayed basis pursuant to the Instructions to Item 5.02(c).</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other Events</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On December 15, 2004,
Jonathan D. Spangler, our Vice President and Chief Patent Counsel<b><font style="font-weight:bold;">,</font></b> adopted a stock trading plan for trading
in NuVasive&#146;s common stock in accordance with the guidelines specified by the
Securities and Exchange Commission&#146;s Rule 10b5-1 under the Securities Exchange
Act of 1934&#160; Mr. Spangler will file Forms
4 evidencing sales under his stock trading plan as required under Section 16 of
the Securities Exchange Act of 1934.&#160;
This type of trading plan allows a corporate insider to gradually
diversify holdings of company stock while minimizing any market effects of such
trades by spreading them out over an extended period of time and eliminating
any market concern that such trades were made by a person while in possession
of material nonpublic information. Consistent with Rule 10b5-1, NuVasive&#146;s
insider trading policy permits personnel to implement Rule 10b5-1 trading plans
provided that, among other things, such personnel are not in possession of any
material nonpublic information at the time they adopt such plans.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the stock
trading plan adopted by Mr. Spangler, the sale of up to 24,000 shares of
NuVasive&#146;s common stock currently held by him or issuable upon the exercise of
stock options may occur.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under Mr. Spangler&#146;s
trading plan, the plan&#146;s agent will undertake to sell specified numbers of
shares each month if the stock trades above certain prearranged minimum
prices.&#160; Mr. Spangler will have no
control over the timing of any sales under the plan and there is no assurance
that any shares will be sold.&#160; Sales
under the trading plan will take effect in March 2005 and continue for one
year.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\tvalley\04-15357-1\task263848\15357-1-ba.htm',USER='tvalley',CD='Dec 28 12:19 2004' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit 99.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Press
release issued by NuVasive, Inc. on December 22, 2004.</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\tvalley\04-15357-1\task263848\15357-1-ba.htm',USER='tvalley',CD='Dec 28 12:19 2004' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.82%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.56%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NUVASIVE</font></b><b><font style="font-weight:bold;">, INC.</font></b>&nbsp;</p>
  </td>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.86%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.86%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: December 28, 2004</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.86%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="33%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;/s/&nbsp;&nbsp;&nbsp;&nbsp;<b><font style="font-weight:bold;">KEVIN C. O&#146;BOYLE</font></b></font></p>
  </td>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.86%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:33.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kevin C. O&#146;Boyle</font></p>
  </td>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.86%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>
  </td>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;text-indent:0in;"><font size="4" face="Times New Roman" style="font-size:13.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\tvalley\04-15357-1\task263848\15357-1-ba.htm',USER='tvalley',CD='Dec 28 12:19 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.08%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>
  Number</font></b></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.96%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description of Document</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:8.08%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:86.96%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release issued by NuVasive, Inc. on December
  22, 2004.</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\tvalley\04-15357-1\task263848\15357-1-ba.htm',USER='tvalley',CD='Dec 28 12:19 2004' -->


</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a04-15357_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>

<head>





</head>

<body lang="EN-US" link="blue" vlink="purple">

<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="252" height="91" src="g153571mmimage002.jpg"></font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PRESS
RELEASE</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contacts:</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investors/Media:</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Kevin C. O&#146;Boyle</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stephanie Carrington/Greg Tiberend</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Chief Financial Officer</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Ruth Group</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NuVasive,
  Inc.</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">646-536-7017/7005</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">858-271-7070</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">scarrington@theruthgroup.com</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.1%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">investorrelations@nuvasive.com</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.3%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="51%" valign="top" style="padding:0in .7pt 0in .7pt;width:51.6%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">gtiberend@theruthgroup.com</font></p>
  </td>
 </tr>
</table>

<p align="center" style="font-size:10.0pt;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font face="Times New Roman">&nbsp;</font></b></p>

<p align="center" style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">NuVasive Announces Executive Promotions</font></b></p>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">San
Diego, CA &#151; December 22, 2004</font></b> &#151; NuVasive, Inc.
(Nasdaq: NUVA), a medical device company focused on developing products for
minimally disruptive surgical treatments for the spine, announced today the
following executive promotions, effective December 17, 2004:</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Keith Valentine
promoted to President</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Kevin O&#146;Boyle
promoted to Executive Vice President and Chief Financial Officer</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pat Miles
promoted to Senior Vice President of Marketing</p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Jonathan
Spangler promoted to Vice President and Chief Patent Counsel</p>

<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In conjunction with these
promotions Alexis V. Lukianov&#146;s title is now Chairman of the Board and Chief
Executive Officer.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alexis V. Lukianov, Chairman
and Chief Executive Officer, remarked, &#147;All four of these individuals have
repeatedly demonstrated their dedication, commitment and drive to achieve
outstanding results. They have been instrumental in driving the progress of our
strategy to expand market penetration of our leading spine surgery products and
technologies. I am proud of their many successes, passion and determination to
meet customer and business needs and I am confident that they will continue to
provide the same level of support and dedication to the growth of our Company.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The promotion of Keith
Valentine is significant since it recognizes the responsibilities that Keith
has already assumed over the last year, working along side me and the NuVasive
team to implement our growth strategy.&#160;
Kevin O&#146;Boyle&#146;s promotion is equally meaningful since it recognizes his
continued responsibilities in working closely with me to manage finance and
operations.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Keith
Valentine</font></b> has served as Executive Vice President of
NuVasive since January&nbsp;2002 and as Senior Vice President of Marketing
&amp; Development since January 2001. Mr. Valentine&#146;s responsibilities include
R&amp;D, regulatory and clinical affairs, quality assurance, marketing,
customer service, distribution and legal patent matters. Prior to joining
NuVasive, he served as</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kr\04-15357-1\task263700\15357-1-mm.htm',USER='kranganathan',CD='Dec 28 19:32 2004' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President of Marketing at
ORATEC Interventions,&nbsp;Inc., a medical device company that was acquired by
Smith&nbsp;&amp; Nephew plc. He also served in various capacities at Medtronic
Sofamor Danek, including Vice President of Marketing for the Rods Division and
Group Director for the BMP Biologics program, the Interbody Sales Development
effort and International Sales and Marketing. Mr.&nbsp;Valentine received a
B.B.A. in Management and Biomedical Sciences from Western Michigan University.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Kevin
O&#146;Boyle</font></b> has served as NuVasive&#146;s Senior Vice President
and Chief Financial Officer since January&nbsp;2003. Mr. O&#146;Boyle&#146;s
responsibilities include finance and accounting, operations, information
technology and investor relations. Prior to joining NuVasive, he served as
Chief Financial Officer and Chief Operating Officer at ChromaVision Medical
Systems,&nbsp;Inc., a publicly traded medical device firm specializing in the
oncology market. Prior to joining ChromaVision, he was Chief Financial Officer
and Senior Vice President of Operations at Albert Fisher North
America,&nbsp;Inc., a publicly traded international food company. Mr.&nbsp;O&#146;Boyle
is a CPA and received a B.S. in Accounting from the Rochester Institute of
Technology and completed the Executive Management Program at the University of
California at Los Angeles John E. Anderson Graduate Business School.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Pat
Miles</font></b> has been Vice President of Marketing at NuVasive
since April of 2002 and Group Director of Neurophysiologic Marketing since
January of 2001. Mr. Miles has recently established new departments to focus on
medical and surgeon education and corporate projects. Prior to joining
NuVasive, he served as Director of Marketing for ORATEC
Interventions,&nbsp;Inc., a medical device company. Prior to that, he served as
Director of Marketing for Minimally Invasive Systems and Cervical Spine Systems
for Medtronic Sofamor Danek. He also served in several sales and marketing
capacities at Smith and Nephew Orthopaedics, a global orthopaedic implant and
instrument manufacturing company from 1992-1997.&#160; Mr.&nbsp;Miles received a B.S. in Finance
from Mercer University.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan
Spangler</font></b> has been Chief Patent Counsel and Group
Director of Intellectual Property at NuVasive since September&nbsp;2001. Prior
to joining NuVasive, he served as Chief Patent Counsel for A-Med
Systems,&nbsp;Inc., a privately held medical technology company. Prior to that,
he practiced law at Arnold White&nbsp;&amp; Durkee, specializing in patent and
trade secret litigation involving medical devices and at Haugen&nbsp;&amp;
Nikolai, specializing in patent prosecution involving medical devices.
Mr.&nbsp;Spangler is licensed to practice law in the States of California and
Minnesota and before the U.S. Trademark Office.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<h2 style="font-weight:normal;margin:0in 0in .0001pt;page-break-after:auto;text-decoration:underline;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">About NuVasive</font></u></h2>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NuVasive is a medical device<b><font style="font-weight:bold;"> </font></b>company focusing on the design, development and marketing
of products for use in minimally disruptive surgical treatments for the spine.
NuVasive&#146;s Maximum Access Surgery (MAS&#153;) product platform includes the
NeuroVision&#174; nerve avoidance system, MaXcess&#153; spine access system, and
specialized implants.&#160; NuVasive also
offers classic fusion implant products for use in spine surgery and has an
R&amp;D pipeline emphasizing motion preservation products such as total disc
replacement (TDR).</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kr\04-15357-1\task263700\15357-1-mm.htm',USER='kranganathan',CD='Dec 28 19:32 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could cause
NuVasive&#146;s results to differ materially from historical results or those
expressed or implied by such forward-looking statements.&#160; All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including statements containing the words &#147;planned,&#148; &#147;expects,&#148; &#147;believes,&#148;
&#147;strategy,&#148; &#147;opportunity,&#148; &#147;anticipates&#148; and similar words.&#160; These statements may include, among others,
plans, strategies and objectives of management for future operations; any
statements regarding proposed new products, services or developments; any statements
regarding future economic conditions or financial or operating performance;
statements of belief and any statements of assumptions underlying any of the
foregoing. The potential risks and uncertainties that could cause actual growth
and results to differ materially include, but are not limited to, the rapidly
changing and competitive nature of the medical device industry, NuVasive&#146;s
ability to convince surgeons to use its products, the ability of patients to
obtain third-party reimbursement for surgical procedures employing NuVasive&#146;s
products, risks related to government regulation of medical devices, risks
related to NuVasive&#146;s ability to effectively manage the growth of its business,
risks related to ownership and enforcement of intellectual property rights,
NuVasive&#146;s ability to successfully develop new products, and other risks and
uncertainties more fully described in NuVasive&#146;s Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission and NuVasive&#146;s Prospectus
filed pursuant to Rule 424 under the Securities Act of 1933, as amended, with
the Securities and Exchange Commission on May 13, 2004.&#160; NuVasive&#146;s public filings with the Securities
and Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events or
circumstances arising after the date on which it was made.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">#&#160;&#160; #&#160;&#160; #</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kr\04-15357-1\task263700\15357-1-mm.htm',USER='kranganathan',CD='Dec 28 19:32 2004' -->


</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g153571mmimage002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g153571mmimage002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=A<F4Z($UI8W)O<V]F="!/
M9F9I8V7_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-#AT5%A$8(Q\E)"(?(B$F
M*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_VP!#`0H+"PX-#AP0$!P[
M*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SO_P``1"`!;`/P#`2(``A$!`Q$!_\0`&P`!``(#`0$`````````
M``````0&`P4'`@'_Q`!!$``!`P,#`04&`P,)"0`````!`@,$``41!A(A,0<3
M05%A%"(R<8&1%4*A(U*Q)3,V<G-TDK+1-#4W.$-3@L'A_\0`&`$!`0$!`0``
M``````````````$"`P3_Q``@$0$!`0$!``("`P$``````````0(1$@,A!#$B
M,D%A_]T`!``H_]H`#`,!``(1`Q$`/P#LU*4H%*4H%*4H%*4H%*4H%*4H%*4H
M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%0;S=6+':9%RDI6IF.`5AL95
M@D#C[U.JM=HG]`[K_9)_SIK69W4C>)+J2HL/M1TI+("ISD8GP?94/U&15B@7
MFV7-.Z!<(TGT:="C]JX=V:V^'<]7MQ9T9N0PIAS+;B<CI70[IV2V.4HNVQU^
MVO\`5);45)!^1Y^QKM\F,9USKU?-\/Q8WY[8O=09]ZMMK<0W.F-L*<&4A1YQ
MY^@]:YE+=[0-`_M7)'XK;4=5KRXD#U_,G[XJ5"U!:->W!D.2?PNX82GN74[T
M+4DDI*#D9/O*]U7!STXKG?CLG9]QQU\&I/6?N?\`'4`0I(4D@@C((\:^UBC1
MT1(K49O.QE`0G)R<`8%5/47:;9=+W]-HND>8VM24J#R6TJ;VJ_-US@<^'A7-
MP7&E8HTEB9&;DQGD/,NI"D.(.4J!\0:RT"E5ZU:R@W?5%PT\Q%E(E6\$O+<2
MD(X('!SGG/E6^2\TI>Q+B"KR"AF@]TI467.1%BO/(0J2ME!5W#)!<7CP`)ZT
M$JE5K2&N[5K3VH6Y#[2XI3O0^$I5SGD`$\<59:!2H-ZNT:Q6>5=)A/<16RM8
M3C)]!GQ/2H6E]41M56HW2+$DQHNXI0N2E*=^.I&">!TS\Z#=TKPT\T^G<TXA
MQ(.,H4"*]T"E>7'$-(*W%I0D=5*.`*PM3X;Z]C,MAQ7[J'`3^E!(I7A;C;>-
MZTISTW'%"\T$!9<0$GHK<,&@]TKRE25I"DJ"@?$'->J!2O!>:"]A<0%?NE0S
M7GVF/_WV_P#&*#+2L:7V5JVH=0HGP"@:CL7:WRICD-B:RY(;SN;2L$C'7[4$
MRE*4"J[KYEV1HBYM,-+=<4VG:A"2HGWAT`JQ5&N*9"[>\F*LI>VY01US5S>6
M5K%YJ5QSLNM=QB:T:=DP)3+89<&]QE21T\R*[95)M=^F-7)L393BF<E*PKP]
M?H:NH((!!R#T(KI\NKK7:[?D;N]^J*2%I*5`%)&"".#7#^T'1KUIU&'+-!D+
MC2$=ZE+#:E!I6>0,#CS'SKN-5K5-PEPY,=,:0MH*020GQYI\6[G7TGX_R:QO
MZ?=!7*XW+2[*[JR\W+946EEY!2I8'17/H?N*HNL[-"U#VUVVU7!"EQY%O(5M
M5@@@.$$'S!`-=&TS*?EVQ3DAU3B^\(RKRP*I%X_Y@[+_`'`_Y7:QK]USW_:M
M'#FW[L:O(@W$.7#34E?[-U(_F\^(_=5YIZ'J*[#;KC#NT!J=`D(D1GD[D.(.
M0?\`[Z4N5LA7>`[`N$=$B,\,+;6.#_H?6N12(E][&[NJ9![VXZ8DK_:MD\M$
M^?DKR/0]#66&XT;_`,:=6_V8_BBH>AFT#MNU3A"1A+N..F7$YK[V<7.+>NU7
M4MR@K*X\F.E;:B,'&4]17S1BT,=N>IFG5!#CJ'-B5<%7O)/'TYH.MUR/2C:$
M]OVH-J`,,N$<>)+>3^IKKE<CT@M,CMYU$ZR=[:6G$E2>@(+8/Z@T$35T1_LT
M[0XVJ[>V?PNXK*932.@)Y6GZ_$/4&NPQ93$V(U*C.)=9>0%MK3T4DC(-0-2V
M"+J:P2K3+'N/H]U>.6UCX5#Y&N2:8U_)T'8KSIJ]()GVPJ$%)R0HDXVY_=!.
MX>A/I0?_T)W:'-D:TU?"T%:W"&6UAZX.IZ)QS@_U1S\R!X58-?75G1^B&[1:
MF0),Q(@P6$C)Y&"<>.`?N14?LHTP[:K,[?[IE5TNY[YQ;GQ);)R`?4_$?IY5
M7$)O_:'KR1J&PO0FX=D<[B&N8E2FU*YRH`#D^.?5-!'T7[=V8Z\1IN[O!4*[
M-H*'1P@.D8!'_EE)^AKM=<AUUHS7=^M'M5REVB2NW!3S0B-K2Z>.0"1Z9QY@
M5<NS?5@U9I1F0ZL&;&PS*'B5`<*^HY^>:#G]ZE1+YVO2K3K2:[&M4?B)'4X6
MVEG`V[CX9Y.?/C-7T=F6D>_B38%O$1Z,ZAYIZ.ZKG:01G)((-;/4FCK%JM@-
MW:$EQ:1A#Z#M<1\E#^!XKF-\M.I^R-MNY62\JFV8NA"XLGG83T!'3G'5.#06
MCMM:;7V?K6I"5+;DME"B.4Y)!Q]*G0M,0M2=E%NL[R$H2[`:4VL#^;<V@A0^
MIY\\GSK2]I]T1>^Q]BZ-H*$RU,.A!_+GG%731O\`0JR_W%G_`""@IG9'?I$=
M,O15W'=7"U*5W23^9O/('G@G/J"/*NB7&?&M5ND3YC@;CQVRXXH^`%<Y[4[)
M*M4^'KVRIQ+MZDB4D?G;Z`G[[3Z'TJ!J?4@[2Y=FTK8'5"/,2F5<7!_TD#G8
M?4?QVT$WLXM;NJ-03^T"[,`*D.%NWMJ'P('N[OH`$@_UJKNG],V"^]JVJ(=W
MBMJC,N.K:1WA;"5=X!Q@CP)KM<&%'ML%B%$;#3$=L-MH'@D#`KBUBTS:=4=K
M^IXEWC%]EM;KB4AQ2,*[P#/!'@30=#LV@-(6>\1[C:6`S+8W;2B2I>X%)!!!
M)\#6:U:.-NO2)RI25MM?``@A2O=*1DYP,`G./B.#7FS]F^E[#=6;G;(*V)+&
M[:KOUJ'((.02?`U:J!2E*!2E*#37;3D>XJ+S1[A\]5`<*^8_]UJF7KWI_P#9
MNL&1&'E[P'R/A]:MU*U--S=YRM-#U1;I(`<68Z_$.#C[UJ-7.MO2(JVG$K3L
M5RDY'6K))M4"7R]$;4?/&#]Q6M>TC;EY[I;S1]%9'ZU99+UK-S+U]TC_`+H5
M_;*_@*U<_1<^9VCPM5HN##;41L-".6B5*3A0/O9Z^\?#RJQVJVIM44QTNEP%
M95DC%1GI4V?=7X$)],5N(E)>>*`M:E*&0E(/`XY).>HJ7[K-_E;8V]8WX[,J
M.Y'D-(=:<24K0L92H'J"*AN3S;UPH;_?3),DE(4VV!TY*E<@`#(K$=16_P#%
M_P`+2IQ;P7W:BE.4I5C."?E]*G*GF_XT&ENSUC2.K9UQMKG\GS(^U+"B2IE>
MX'`/BG]:]:N[.86I9[=WB37K5=V<;);'YL=-PR.1Y@CZU8Q>(QNXM92L/*2I
M23E)!QC/0Y'4=0*B"_+7:I\TQU,",\MEHK&X.$*V@X!_>XQ3E/-55S27:-)C
M^QOZX:3'/"G&HP#I'S`!_6K#H[1%LT9"<:AE;\E\@ORG?C</EZ#KQ6SE7B-!
M?6P^'.\0P'O=3G>-VW"?,Y(&/45AGZDM]MF-Q'RX7E)2I24(W;`3@9^N>F>E
M.4F;6VJEZI[.+?J;5-LO3Q2D1U8EMX_VA(Y2/OP?3Y5<'E.)8<4R@+<"24))
MP%''`S6CL]Z*K9*F3Y3BGHC>Z5%4P$+CJ`)(`ZD'P.3GSI)TF;9UFU3:[G>+
M&];;5-:@JD)+;CRT%12@CD)P1@GIFONDM.LZ6TW$M#12LLIRXXD8[Q9Y4JL@
MOS*HDYU3#\9R&SWRVWT#.TI)!X//0\9\*^2K\U`2A,AA]UQ,;VAXLMC:A/0D
MY/SXY/!IRGFMM5#L'9_/TUK.;>+;<H[=NFN$NP2RKX2<C!SP0>G'B15GN.H[
M=:Y+<=]2U.+0%E+:<[4DX!/^@YX/%;0\C@XIQ++/VITZRZ[:NTN1:-20O8WW
M-[<>9'*NZ]`1SBM9<.SW4>JW64:LU,VY":7O]D@L;`H_,_7D@U8HDZ8Q+N;T
MZ[9@VU82HEA(W>X%*SCRW#I4V-J2WR8+\P%UMN.0%A:.23C``&<DYQCSXJW-
M:N+&JUCHQ6H-),Z=MS[,&.TIO!4@JVH0.``"/2MU8+<]:+!!MK[J'7(C"62M
M"2`K:,`X/H*P72[R(]F7)9BOLOEUMIMMQ`*E%2DC@`G/!-9/Q^/[")/L\G<9
M'LW<[!O[S.,=<?7/2IRIYO.MA(8:E1W([[:7&G4%"T*&0I)&"#54T+V?Q-%*
MN#C;@?=E/'8LCE#(/NH^?GY\>5;T7R*8*)7=O;EO%A+&S+A<!(*0,X\#SG&!
MG-8)=Z+EH5(AA34@R41MCJ.4+*PD@CY'-.4\UN:YHCLWU+#U3<K_`&K4T:$_
M<%K*P(F\!*E;L>\3Y#FKQ*OT6)(6TIMY:6EH0\ZA&4-*5C`4?J.F<9&:\7'4
M4:VNNH5'DOA@)+ZV4`AK=\(.2.3Y#/%.4\VJRO3':&Z@H7KII*5<$H@("L>A
M\*O#+098;:"E+V)"=RSDG`ZD^)J))N\:+)5&<2YWH2A24I3DKWJ*0$^9R.?*
MH-I1?TWN6JX+!A'/=#W<#GC;CGIYTX>?KK>TI2HR4I2@4I2@4I2@5KI5F:?F
M*F,RI,1]Q`0XJ.L#O`.F001D9//6MC2G>++8BB`T)3$DJ<6XPTII!4K/"L9)
M]?='-8V+6W&FNR&7WTI>67%L[AL*B,$],_KBIU*O3M:R'8HL*<9C:W5+/>;4
MJ4"E.]04KPSU'B37M-EBI@F%N=4SW_?X*NAW[\9\MU;"E.U?51)%MBRIT:8\
MC<[%W=V<\#..H\>E>%VMM5Q,YM]]EQ82EQ+:AM<"2<9!'J>F*G4IVIVL;[1>
M84VEU;14.%MD;D_+(-:>?I_?;YC+#CKLB>IM+[[KF%=V%#.,#`PG=@`=36\I
M26Q9JS]-8+#%]CE1W7'WC,P'W7%Y6L#@#..!CP`\36259XLQ4E3N_,EI+*\*
MQ[B22`/\1J?2G:>J@NVMM=P]M;??8<4E*'`VH!+@220""#YGICK4ZE*B=ZUY
MLL-429%4%E$UQ3KIW<[CCD'PQ@8^5>G+6V_`5$DR'WPI04'%J`6D@@@@@#&"
M`:G4J]IZJ$JV-NM,(??>?+#P>2I:ADJ&<9P`,<U\1:(J`R!O/<R%R1E75:MV
M2?/XC^E3J4[3U6M58XQB-1T./-EAY3S;J%^^E:BHDYQ@YW$<CQKVBS1$,,,C
M?AE_VC)5DK<Y.5'QY.?M4^E.U?5:URQ1'9:WU+>V.N)=<8W_`+-:TXPHCZ#C
M..!Q6LFV&=-O#B]W=179+3SA0][K@1C`4C'Q92!D'&,<9%66E6:L6;L:XV\R
M+Z)[[:0(K1;CG.22KE2C]@!]?.MC2E9ZS;TI2E$?_]'LU*4H%*4H%*4H%*4H
G%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H/__9
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
